The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.

The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.

This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.

Provided herein are compositions, systems, kits, and methods for treating a patient with a thromboembolism by administering nanoconjugates comprising nanoparticles encapsulating and/or conjugated to: i) tissue-type plasminogen activator (tPA), and ii) at least one antioxidant enzyme selected from the group consisting of: superoxide dismutase, glutathione peroxidase, glutathione reductase, and a catalase.

The invention relates to molecular biology, biotechnology, medicine, veterinary science. A group of inventions is proposed: a fusion protein comprising a ligand to MATN1 protein, and a growth factor of EGF, TGF, FGF, IGF, connected via a flexible link; such fusion protein further comprising the Fc-fragment of an antibody or a polypeptide binding with FcRn and/or transferrin or a fragment thereof, connected via a flexible link; encoding polynucleotide, a genetic construct for the synthesis of the fusion protein in producer cells, or cells of a target organism, the fusion protein producer, a producer of the genetic construct, a preparation for the regeneration of cartilage containing at least 1 fusion protein or genetic construct, for parenteral or, in the case of the preparation based on at least 1 fusion protein containing the transport domain, —oral administration, in the latter case the preparation is enclosed in an enteric coating.

Disclosed herein is a biomolecule comprising a synthetic peptide for targeting thrombus, a pharmaceutical composition comprising the same, and uses thereof in the treatment of thromboembolism-related diseases. According to embodiments of the present disclosure, the synthetic peptide having the amino acid sequence of SEQ ID NO: 1, 2, or 3 exhibits a binding affinity and specificity to thrombus. Thus, the synthetic peptide may serve as a targeting element for delivering a therapeutic agent (e.g., an anticoagulant agent or a thrombolytic agent) to the thrombus thereby improving the therapeutic safety and efficacy of the therapeutic agent.

Compositions for and methods of treating corneal injury, among other tissue of or around the eye, are provided. Said compositions comprise MG53 or express MG53. Said compositions can be used for treating chronic or acute injured tissue of the eye or orbit of the eye and can be administered systemically, locally, or both.

The present disclosure provides a polypeptide including an anti-fibrin antibody and a serine protease moiety of human tissue plasminogen activator. Methods for treating thrombosis in a subject in need of such treatment using such polypeptide are also disclosed.

The present invention relates to a novel process of isolating and purifying tissue plasminogen activator and its variants more specifically TNK-tPA from CHO cells and describes an industrially applicable, simple, cost effective, robust and highly efficient process of TNK-tPA purification.

The present invention is directed to methods of treatment of airway obstruction associated with fibrin-containing cast formation by administering a fibrinolytic agent.